Companies / BOC Sciences / Siplizumab
BOC Sciences

Siplizumab | BOC Sciences

Siplizumab is a humanized IgG1 monoclonal antibody directed against CD2. Siplizumab was shown to deplete T cells globally while promoting expansion of regulatory T cells early post-transplant. Siplizumab is under investigation as a tolerance induction agent in RTR.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.